In yesterday’s Wall Street session, Roivant Sciences Ltd (NASDAQ:ROIV) shares traded at $9.75, down -0.51% from the previous session.
10 analysts cover Roivant Sciences Ltd (NASDAQ:ROIV), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $11.00, we find $15.50. Given the previous closing price of $9.80, this indicates a potential upside of 58.16 percent. ROIV stock price is now 1.63% away from the 50-day moving average and 1.09% away from the 200-day moving average. The market capitalization of the company currently stands at $7.84B.
The stock has received a hold rating from 1 analysts and a buy rating from 9. Brokers who have rated the stock have averaged $15.75 as their price target over the next twelve months.
With the price target of $17, Guggenheim recently initiated with Buy rating for Roivant Sciences Ltd (NASDAQ: ROIV).
In other news, Venker Eric, Chief Operating Officer sold 153,027 shares of the company’s stock on Oct 05. The stock was sold for $1,547,103 at an average price of $10.11. Upon completion of the transaction, the Chief Operating Officer now directly owns 595,397 shares in the company, valued at $5.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 03, Chief Operating Officer Venker Eric sold 606,221 shares of the business’s stock. A total of $6,213,765 was realized by selling the stock at an average price of $10.25. This leaves the insider owning 595,397 shares of the company worth $5.81 million. A total of 32.37% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $6.39 and a high of $13.24. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 5.84, and a quick ratio of 5.82. The fifty day moving average price for ROIV is $9.59 and a two-hundred day moving average price translates $9.65 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.4, missing analysts’ expectations of -$0.31 by -0.09. This compares to -$0.45 EPS in the same period last year. The net profit margin was -951.76% and return on equity was -103.96% for ROIV. The company reported revenue of $37.1 million for the quarter, compared to $12.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 196.03 percent. For the current quarter, analysts expect ROIV to generate $31.15M in revenue.
Roivant Sciences Ltd(ROIV) Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn’s disease. The company was founded in 2014 and is based in London, the United Kingdom.
